HCV-IN-44 (compound 28) is an inhibitor of the HCV NS5B protein, efficacious in suppressing HCV virus replication and useful for researching HCV infection [1].

HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM). It shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake.

HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor (IC50: 20 μM; Kd: 29 μM).

HCV-371 is a potent selective HCV NS5B polymerase inhibitor that shows broad inhibitory activity against NS5B RDRP and no inhibitory activity against a set of human polymerases (including mitochondrial DNA polymerase γ and other unrelated viral polymerase

HCV-IN-34 is an orally active HCV entry inhibitor. HCV-IN-35 exhibits good antiviral efficacy (EC50: 0.010 μM, CC50 (half of the maximum cytotoxic concentration): 7.50 μM).

HCV Core Protein (59-68) is a peptide comprising residues 59-68 from the core protein of the Hepatitis C virus (HCV) [1].

HCV-IN-39 (Compound 18a) is a potent, orally active nucleoside inhibitor of hepatitis C virus (HCV) that acts on the GT1a replicon (EC50: 0.259 μM), GT1b replicon (EC50: 0.434 μM) and GT1b CES1 replicon (EC50. 0.069 μM).

HCV-IN-35 is a potent inhibitor of HCV and shows potential for infectious disease research.

HCV-IN-33 (Compound (S)-3i) is an inhibitor of HCV entry.

HCV-IN-29 is a hepatitis C virus (HCV) inhibitor.

HCV NS4A Protein (18-40) (JT strain) is a peptide derived from residues 18 to 40 of the HCV NS4A protein. It enhances the catalytic efficiency of NS3 protease [1].

HCV Peptide (131-140) is a research-grade peptide utilized in the study of the hepatitis C virus (HCV) [1].

HCV-086, a RNA-directed RNA polymerase (NS5B) inhibitor, is used for the treatment of HCV infection.

HCV-IN-36 is an orally active HCV entry inhibitor that exhibits good antiviral activity (EC50: 0.016 μM, CC50 (half of the maximum cytotoxic concentration): 8.78 μM).

HCV-IN-43 (compound 2), an HCV NS5B protein inhibitor, efficiently inhibits HCV virus replication and is utilized in the study of HCV infection [1].

HCV-IN-37 is a potent inhibitor of HCV. HCV-IN-37 is able to persist in rat plasma after oral administration to rats at a single dose of 15 mg/kg. The high potency of the active derivative HCV-IN-37 is mainly driven by the inhibition of the entry phase of the virus.

HCV-1 e2 Protein (554-569), a primary antigenic region within the Hepatitis C Virus envelope 2 (e2) protein, features a putative N-glycosylation site believed to impact the immune recognition of e2 [1].

HCV Core Protein (107-114), identified as the binding site within the region 101-118, is a minimally immunogenic fragment of the primary linear HCV core regions. This segment, comprising two residues that vary between genotypes I/II and III/VI, represents a potential focal point for the dissemination of HCV serotypes [1].

HCV-IN-4, a potent and orally active inhibitor of HCV NS5A, demonstrates significant efficacy against genotypes GT1a, GT2b, GT3a, and the GT1a mutations Y93H and L31V. Its half-maximal effective concentrations (EC90s) are 3 pM, 0.3 nM, 0.01 nM, 0.5 nM, and 0.02 nM, respectively[1].

HCV-IN-30 is an HCV NS5A replication complex inhibitor (IC50s: 901 and 102 nM for genotypes 1a and 1b replicons).

HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor (IC50s: 3-47 pM). It shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake.

HCV-1 e2 Protein (554-569) TFA, an antigenic segment of the hepatitis C virus envelope 2 (e2) protein, encompasses a potential N-glycosylation site implicated in modulating immune recognition of e2 [1].

HCV Peptide (257-266) is a peptide utilized in hepatitis C virus (HCV) research [1].

HCV-1 e2 Protein (484-499) is a 16-amino acid peptide derived from the envelope 2 protein of the hepatitis C virus, identified in the sera of individuals possessing antibodies to HCV [1].

HCV-IN-41 (compound 4), a potent inhibitor of the hepatitis C virus (HCV), demonstrates exceptional inhibitory effectiveness across different genotypes, with EC 50 values of 0.006762 nM for genotype 1b, 5.183 nM for 2a, 1.365 nM for 3a, and 142.2 nM for 4a, respectively. It effectively reduces HCV RNA replication [1].

HCV Peptide (35-44), a core protein of Hepatitis C Virus located at positions 35 to 44, functions as an HLA-A2-restricted CTL epitope and inhibits NK cell activity through two distinct mechanisms: directly through the KIR2DL2/3 receptor and synergistically via the CD94:NKG2A receptor [1].

HCV-IN-31 is a HCV inhibitor with an EC50/EC95 of 15.7 μM.

HCV-IN-38 is a selective, potent, orally active hepatitis C virus (HCV) inhibitor with an EC50 value of 15 nM and an SI value of 431. HCV-IN-38 has a good safety profile and oral pharmacokinetics, exhibiting high anti-HCV activity and low cytotoxic effects.

Nesbuvir is a selective hepatitis C virus (HCV) nonstructural protein 5B (NS5B) RNA-dependent polymerase inhibitor.Nesbuvir has an IC50 of 9 nM against hepatocellular carcinoma cells containing 1b HCV replicons.

Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.

Artemisinin (Qinghaosu) is an ancient Chinese herbal therapy for malarial fevers which has been recently found to have potent activity against many forms of malarial organisms, including chloroquine-resistant Plasmodium falciparum.

Filibuvir (PF-00868554) is a selective and noncovalent inhibitor of HCV NS5B RNA-dependent RNA polymerase. Filibuvir inhibits genotype 1a and 1b replicons with EC50s of 59 nM.

EIDD-1931 (Beta-d-N4-hydroxycytidine) is a ribonucleoside analog with antiviral activity.It inhibits replication of severe acute respiratory syndrome coronavirus (SARS-CoV) in Vero 76 cells, Middle East respiratory syndrome coronavirus (MERS-CoV) in Calu-3 2B4 cells, and SARS-CoV-2 in Vero cells (IC50s =0.1, 0.15 and 0.3 μM, respectively)

VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.

7-benzyl-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine is a inhibitor of Hepatitis C Virus(HCV).

BILB-1941 (BILB-1941ZW) is an inhibitor of HCV NS5B polymerase and can be used in studies about HCV infection.

MK-8325 is a potent and orally available HCV NS5A inhibitor with replicative activity against a wide range of genotypes.MK-8325 has demonstrated bioavailability in in vitro and in vivo assays and has a favorable overall ADME profile.

2’-beta-C-Methyl inosine (2’-C-Methylinosine) is an HCV RNA polymerase inhibitor with antiviral activity and is being studied for the treatment of hepatitis C virus infection.

Isatoribine(ANA245) free base is a potent TLR7 receptor agonist with anti-hepatitis C virus infection activity for the study of HCV infection.

CHLORCYCLIZINE is a histamine H1 antagonist and a potent hepatitis C virus (HCV) entry inhibitor.

ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).

TMC647055 Choline Hydroxide Salt is a novel and potent non-nucleoside inhibitor of the HCV NS5B polymerase which potentially for the treatment of HCV infection. It has nanomolar cellular potency (EC(50) of 82 nM) with minimal associated cell toxicity (CC(

Sovaprevir is a non-structural 3 (NS3) protease inhibitor with antiviral activity for the treatment of HCV infection.

Setrobuvir (ANA-598) is an orally active non-nucleoside HCV NS5B polymerase inhibitor with inhibitory effects on de novo RNA synthesis and primer extension with IC50s between 4 and 5 nM. setrobuvir shows good binding affinity for SARS-CoV-2 RdRp and induces inhibition of RdRp.

BMS-929075 is an orally active HCV NS5B replicase (HCV NS5B replicase) palm site variant inhibitor with potency, high oral bioavailability and pharmacokinetic parameters.BMS-929075 shows cytotoxicity.

TMC-649128 PM is a potent nucleoside inhibitor of the HCV NS5B RNA-dependent RNA polymerase, displaying an EC(50) value of 1.2 muM and showing moderate in vivo bioavailability in rat (F=14%).

IDX184 is a potent, orally active, targeted HCV polymerase inhibitor and nucleoside polymerase.IDX184 effectively inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM). IDX184 is a liver-targeted nucleotide prodrug with anti-HCV activity that inhibits HCV NS5B polymerase and can be used in combination with pegylated interferon-α2a and ribavirin for the primary treatment of chronic hepatitis C. It has been shown to inhibit HCV polymerase and nucleoside polymerase.

GS-443902 trisodium (GS-441524 triphosphate trisodium), the active triphosphate metabolite of Remdesivir (GS-5734), serves as a potent inhibitor of viral RNA-dependent RNA-polymerases (RdRp), displaying inhibitory concentrations (IC50) of 1.1 μM and 5 μM for RSV RdRp and HCV RdRp, respectively.

HCVP-IN-1 (compound 1) is a hepatitis C viral polymerase (HCVP) inhibitor.

HCVcc-IN-1, a derivative of benzothiazole-2-thiophene S-glycoside, exhibits low toxicity and antiviral properties [1].